promising gene therapy stock faces key catalysts By Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for severe neurological conditions. The company’s lead candidate, TSHA-102, is being developed to treat Rett syndrome, a rare genetic disorder that primarily affects females and is characterized by severe impairments in cognitive, sensory, emotional, motor and autonomic function.
TSHA-102 and the Rett Syndrome Opportunity
TSHA-102 represents a significant market opportunity, with analysts estimating the Rett syndrome treatment market at approximately $2.5 billion. The therapy uses a novel approach, employing a miniMeCP2 transgene delivered via intrathecal administration, which has shown promising safety data in early…
